Pharmacotherapy for Schizophrenic Drug Users - 6

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000281

Purpose

The purpose of this study is to evaluate maintenance neuroleptics for Schizophrenic patients who are cocaine abusers.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Behavioral: Amantadine	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Pharmacotherapy for Schizophrenic Drug Users

Resource links provided by NLM:

Drug Information available for: Amantadine sulfate Amantadine hydrochloride Amantadine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Retention
Psychological symptoms
Schizophrenic symptoms

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000281

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

Study ID Numbers:	NIDA-09250-6, P50-09250-6
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000281 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Anti-Infective Agents
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Disorders of Environmental Origin
Antiparkinson Agents
Antiviral Agents
Pharmacologic Actions

Pathologic Processes
Sensory System Agents
Analgesics, Non-Narcotic
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Dopamine Agents
Peripheral Nervous System Agents
Analgesics
Amantadine
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009